StreetInsider.com News Articles

GRAIL to Announce Third Quarter 2026 Financial Results

Wed, 21 Oct 2026 16:02:00 -0400

SUNNYVALE, Calif., Oct. 21, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2026 following the close of market on Wednesday, Nov. 4, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress.

GRAIL to Announce Third Quarter 2026 Financial Results

Wed, 21 Oct 2026 16:02:00 -0400

Form 4 GRAIL, Inc. For: Oct 15 Filed by: SUMME GREGORY L

Fri, 16 Oct 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20261016/27198469.html

Form 4 GRAIL, Inc. For: Oct 15 Filed by: CHASE WILLIAM J

Fri, 16 Oct 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20261016/27198470.html

Form 4 GRAIL, Inc. For: Oct 15 Filed by: MIZELL STEVEN

Fri, 16 Oct 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20261016/27198467.html

Form 4 GRAIL, Inc. For: Oct 15 Filed by: Ofman Joshua J.

Fri, 16 Oct 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20261016/27198468.html

Form 144 GRAIL, Inc. Filed by: Ofman Joshua J.

Thu, 15 Oct 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20261015/27193910.html

GRAIL, Inc. (GRAL) PT Raised to $120 at Morgan Stanley

Tue, 13 Oct 2026 08:24:09 -0400

Morgan Stanley analyst Kallum Titchmarsh raised the price target on GRAIL, Inc. (NASDAQ: GRAL) to $120.00 (from $60.00) while maintaining a Equalweight rating.

GRAIL, Inc. (GRAL) PT Raised to $180 at TD Cowen

Tue, 13 Oct 2026 05:31:46 -0400

TD Cowen analyst Dan Brennan raised the price target on GRAIL, Inc. (NASDAQ: GRAL) to $180.00 (from $88.00) while maintaining a Buy rating.

The analyst comments "We raise our PT to $180 from $88 post the favorable FDA AdComm & greater confidence in CMS reimbursement & we assume ~70% probability of CMS coverage > our 50% prior (given KOL diligence & AdComm). Discussions reflect the debate post FDA approval will focus on structure & breadth of coverage vs a binary coverage decision. We also shift our EV/S PT framework to 2033 as our base year (vs 2030 prior)."

GRAIL, Inc. (GRAL) PT Raised to $180 at TD Cowen

Tue, 13 Oct 2026 05:31:46 -0400

TD Cowen analyst Dan Brennan raised the price target on GRAIL, Inc. (NASDAQ: GRAL) to $180.00 (from $88.00) while maintaining a Buy rating.

GRAIL, Inc. (GRAL) PT Raised to $155 at Baird

Thu, 08 Oct 2026 07:23:21 -0400

Baird analyst Catherine Schulte raised the price target on GRAIL, Inc. (NASDAQ: GRAL) to $155.00 (from $118.00) while maintaining a Outperform rating.

Form 4 GRAIL, Inc. For: Oct 05 Filed by: Freidin Aaron

Wed, 07 Oct 2026 18:36:00 -0400

si-local-file:///var/storage/secattach/20261007/27162188.html

Form 4 GRAIL, Inc. For: Oct 05 Filed by: Partridge Andrew John

Wed, 07 Oct 2026 18:36:00 -0400

si-local-file:///var/storage/secattach/20261007/27162189.html

GRAIL, Inc. (GRAL) call put ratio 1.8 calls to 1 put into medical conferences presentations

Tue, 06 Oct 2026 05:19:07 -0400

GRAIL, Inc. (NASDAQ: GRAL) 30-day option implied volatility is at 87; compared to its 52-week range of 70 to 119. Call put ratio 1.8 calls to 1 put into medical conferences presentations.

Form 144 GRAIL, Inc. Filed by: Partridge Andrew John

Mon, 05 Oct 2026 19:54:00 -0400

si-local-file:///var/storage/secattach/20261005/27150449.html

Form 144 GRAIL, Inc. Filed by: Freidin Aaron

Mon, 05 Oct 2026 19:53:00 -0400

si-local-file:///var/storage/secattach/20261005/27150447.html

GRAIL to present cancer detection data at two medical conferences

Mon, 05 Oct 2026 16:01:16 -0400

GRAIL, Inc. (Nasdaq: GRAL) will present eight abstracts at two upcoming medical conferences, sharing data from its NHS-Galleri trial and PATHFINDER 2 study on its Galleri multi-cancer early detection (MCED) test, according to a company press release.

Six abstracts will be presented at the Early Detection of Cancer Conference (EDCC) in Edinburgh, United Kingdom, from Oct. 6-8, 2026. Two additional abstracts will be presented at the European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, from Oct. 23-27, 2026.

At EDCC, presentations will include a poster estimating the preclinical detection window using NHS-Galleri trial data, a poster on cancer detection across

GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026

Mon, 05 Oct 2026 16:01:00 -0400

GRAIL to Present Six Abstracts at the Early Detection of Cancer Conference (EDCC) Spanning Clinical Performance, Health Equity, and Real-World Implementation of Multi-Cancer Early Detection

GRAIL to Present Two Abstracts at the European Society for Medical Oncology (ESMO) Congress, Across the Cancer Diagnostic Journey and Real-World Evidence

GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026

Mon, 05 Oct 2026 16:01:00 -0400

GRAIL to Present Six Abstracts at the Early Detection of Cancer Conference (EDCC) Spanning Clinical Performance, Health Equity, and Real-World Implementation of Multi-Cancer Early Detection

GRAIL to Present Two Abstracts at the European Society for Medical Oncology (ESMO) Congress, Across the Cancer Diagnostic Journey and Real-World Evidence

GRAIL, Inc. (GRAL) PT Raised to $155 at Guggenheim

Thu, 01 Oct 2026 08:48:06 -0400

Guggenheim analyst Subbu Nambi raised the price target on GRAIL, Inc. (NASDAQ: GRAL) to $155.00 (from $75.00) while maintaining a Buy rating.

GRAIL, Inc. (GRAL) PT Raised to $150 at Canaccord

Mon, 28 Sep 2026 06:41:02 -0400

(Updated - September 28, 2026 6:41 AM EDT)

Canaccord analyst Kyle Mikson raised the price target on GRAIL, Inc. (NASDAQ: GRAL) to $150.00 (from $80.00) while maintaining a Buy rating.

The analyst commented: "We reiterate our BUY rating on GRAIL (GRAL) shares and increase our price target to $150 from $80. Our price target raise is driven by increased revenue estimates throughout our 10-year DCF model following our recent constructive discussion with experts. On Friday, September 25, we hosted a virtual webcast of two key opinion leaders (KOLs) to discuss the recent FDA Advisory Committee (AdCom) meeting (9/23) for GRAIL's Galleri multi-cancer

GRAIL, Inc. (GRAL) PT Raised to $150 at Canaccord

Mon, 28 Sep 2026 06:41:02 -0400

(Updated - September 28, 2026 6:41 AM EDT)

Canaccord analyst Kyle Mikson raised the price target on GRAIL, Inc. (NASDAQ: GRAL) to $150.00 (from $80.00) while maintaining a Buy rating.

GRAIL, Inc. (GRAL) PT Raised to $100 at Mizuho

Fri, 25 Sep 2026 06:44:56 -0400

(Updated - September 25, 2026 6:44 AM EDT)

Mizuho analyst Bradley Bowers raised the price target on GRAIL, Inc. (NASDAQ: GRAL) to $100.00 (from $65.00) while maintaining a Neutral rating.

The analyst commented: "Ultimately what matters for GRAL out of the 9/23 Advisory Committee (AdComm) are votes on the final three questions asking whether Galleri is Safe for patients, Effective for use, and whether the benefits of using Galleri outweigh the risks. The votes were that Galleri is Safe (10 votes Yes to 0), Effective (6 yes 4 no), and the benefits outweigh the risks (7 yes, 2 no, 1 abstain). Overall

GRAIL, Inc. (GRAL) PT Raised to $100 at Mizuho

Fri, 25 Sep 2026 06:44:56 -0400

(Updated - September 25, 2026 6:44 AM EDT)

Mizuho analyst Bradley Bowers raised the price target on GRAIL, Inc. (NASDAQ: GRAL) to $100.00 (from $65.00) while maintaining a Neutral rating.

Canaccord Reiterates Buy Rating on GRAIL, Inc. (GRAL)

Thu, 24 Sep 2026 05:57:53 -0400

Canaccord analyst Kyle Mikson reiterated a Buy rating and $80.00 price target on GRAIL, Inc. (NASDAQ: GRAL)

The analyst comments "We reiterate our BUY rating on GRAIL (GRAL) shares and maintain our price target at $80 (we will review our estimates and DCF model assumptions in the near term). We remain bullish on GRAL shares, as the AdCom meeting for the company's Galleri test went generally better than we expected, with the panel voting in support of approval (while noting the test should not be used to replace guideline-recommended single-cancer screening options). On Wednesday, September 23, the FDA Molecular and Clinical